The connection between Primary sclerosing cholangitis (PSC) and lymphoma remains uncertain. To address this, Mendelian randomization (MR) was utilized to investigate the potential causal links between PSC and lymphoma. A 2-sample MR analysis was conducted utilizing summary-level data obtained from genome-wide association study datasets. Four complementary MR methods were performed, including inverse-variance weighting (IVW), MR-Egger, weighted median, and MR-robust adjusted profile score (MR-RAPS). Several sensitivity analyses were also employed to further validate the results. The results of IVW estimates showed that there was a potential causal association between PSC and diffuse large B-cell lymphoma (DLBCL) risk (OR = 1.138, 95% CI = 1.052-1.230, P = .001). No causal association was observed between PSC and other lymphoma subtypes. No horizontal and directional pleiotropy was observed in the MR studies. This study represents the inaugural utilization of MR analysis to investigate the causal associations between PSC and DLBCL. Further investigation is warranted to elucidate the underlying mechanism of this causal relationship.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11596531 | PMC |
| http://dx.doi.org/10.1097/MD.0000000000040542 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Causal effect of primary sclerosing cholangitis on diffuse large B-cell lymphoma: A two-sample Mendelian randomized study.
Medicine (Baltimore)
November 2024
Department of Hematology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
The connection between Primary sclerosing cholangitis (PSC) and lymphoma remains uncertain. To address this, Mendelian randomization (MR) was utilized to investigate the potential causal links between PSC and lymphoma. A 2-sample MR analysis was conducted utilizing summary-level data obtained from genome-wide association study datasets.
View Article and Find Full Text PDF[Pulmonary sarcomatoid carcinoma:report of three cases].
Zhonghua Jie He He Hu Xi Za Zhi
October 2024
Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing 100029, China.
Article Synopsis
- * This text discusses three cases of PSC with specific genetic mutations (EGFR L858R, BRAF V600E, ALK) and their clinical characteristics.
- * The aim is to enhance treatment options for PSC patients by reviewing literature and providing evidence for genetic testing and the use of targeted therapies.
Whole-genome sequencing of 20 cholangiocarcinoma cases reveals unique profiles in patients with cirrhosis and primary sclerosing cholangitis.
J Gastrointest Oncol
February 2023
Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Background: Cholangiocarcinoma (CCA) is a molecularly heterogenous disease that is often fatal. Whole genome sequencing (WGS) can provide additional knowledge of mutational spectra compared with panel sequencing. We describe the molecular landscape of CCA using whole-genome sequencing and compare the mutational landscape between short-term and long-term survivors.
View Article and Find Full Text PDF'Off the shelf' immunotherapies: Generation and application of pluripotent stem cell-derived immune cells.
Cell Prolif
April 2023
State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
In recent years, great strides have been made toward the development of immune cell-based therapies in the treatment of refractory malignancies. Primary T cells and NK cells armed with chimeric antigen receptors have achieved tremendous clinical success especially in patients with leukaemia and lymphoma. However, the autologous origin of these effector cells means that a single batch of laboriously engineered cells treats only a certain patient, leading to high cost, ununiform product quality, and risk of delay in treatment, and therefore results in restricted accessibility of these therapies to the overwhelming majority of the patients.
View Article and Find Full Text PDFNovel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma.
J Immunother Cancer
January 2023
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA.
Background: Cell therapies for solid tumors are thwarted by the hostile tumor microenvironment (TME) and by heterogeneous expression of tumor target antigens. We address both limitations with a novel class of chimeric antigen receptors based on plant lectins, which recognize the aberrant sugar residues that are a 'hallmark' of both malignant and associated stromal cells. We have expressed in T cells a modified lectin from banana, H84T BanLec, attached to a chimeric antigen receptor (H84T-CAR) that recognizes high-mannose (asparagine residue with five to nine mannoses).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!